Previous 10 | Next 10 |
home / stock / aps:cc / aps:cc news
SAN DIEGO and TORONTO, May 04, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, Pr...
SAN DIEGO and TORONTO, April 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter end...
2023-04-12 15:02:41 ET Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide si...
SAN DIEGO and TORONTO, April 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic maligna...
SAN DIEGO and TORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the company will be participating...
─ APTIVATE Expansion Trial of Tuspetinib as Single Agent in Relapsed/Refractory AML Patients is Up and Running; Initiated Enrollment of Combination Treatment Arm with Venetoclax ─ ─ RAS Mutated AML Clinically Sensitive to Tuspetinib ─ ─ Continu...
SAN DIEGO and TORONTO, March 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies...
SAN DIEGO and TORONTO, March 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the fourth quarter a...
SAN DIEGO and TORONTO, March 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman,...
• AML Patients Receive Tuspetinib Monotherapy to Kick Off APTIVATE Phase 1/2 Trial • New Response Emerges with 40 mg Tuspetinib in FLT3 Wildtype AML Patient • Aptose Elucidates Rationale for Tuspetinib’s Superior Safety Profile ...
News, Short Squeeze, Breakout and More Instantly...
Aptose Biosciences Inc. Company Name:
APS:CC Stock Symbol:
TSXC Market:
Aptose Biosciences Inc. Website:
SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, t...
A look at the top 10 most actives in Canada BetaPro Natural Gas Leveraged Daily Bull ETF (HNU) fell 11.1% to $2.63 on volume of 13,371,978 shares Baytex Energy Corp. (BTE) fell 1.4% to $5.08 on volume of 13,132,263 shares Enbridge Inc. (ENB) rose 0.7% to $49.58 on volume of 10,761,843 sha...
A look at the top 10 most actives in Canada Calibre Mining Corp. (CXB) fell 2.9% to $1.835 on volume of 79,684,444 shares Canadian Natural Resources Limited (CNQ) rose 1.6% to $48 on volume of 6,456,525 shares Alaris Equity Partners Income Trust 5.50% convertible unsecured subordinated de...